A trial fibrillation (AF) affected 2.2 million Americans and 4.5 million Europeans in 2006. 1 Several cardiovascular conditions are known to cause AF, including cardiomyopathies, 2 mitral valve disease, 3 myocarditis, 4 and hypertension. 5 Heart failure (HF), one of the most common causes of AF, 6 produces atrial electric and structural alterations, with atrial tissue fibrosis being a major component. 6 In a canine model of ventricular tachypacing-induced HF, progressive atrial fibrosis is associated with the AF substrate. 7, 8 Recovery from HF reverses the hemodynamic and electrophysiological consequences, but AF promotion and atrial fibrosis remain. 9 Angiotensin-converting enzyme inhibitors suppress fibrosis and AF promotion. 7 Renin-angiotensin system inhibitors may protect patients with HF from AF. 10 
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Fibroblasts secrete extracellular matrix components and regulators, such as collagen, fibronectin, matrix metalloproteases, and tissue inhibitors of metalloproteinases. 11 HF fibroblasts proliferate and differentiate to become myofibroblasts under the influence of paracrine and autocrine factors. 11, 12 Myofibroblast activation increases production of collagen, fibronectin, and cytokines that regulate extracellular matrix production and breakdown, leading to extracellular matrix accumulation and fibrosis. 12 Recently, small endogenous noncoding RNAs, called microRNAs (miRs), have been shown to bind 3′-untranslated regions of target mRNAs to alter protein translation and mRNA stability 13 and to participate in ventricular remodeling.
and that miR-21 knockdown suppresses adverse ventricular remodeling. MiR-21 targets Sprouty-1, a negative regulator of extracellular signal regulated kinases (ERK1/2), which enhance fibroblast survival and density. 16 Thus, miR-21 is a candidate to participate in AF-promoting atrial fibrotic remodeling. It is important to clarify unresolved mechanisms underlying the AF substrate to design novel approaches to clinical management. 17 The present study was designed (1) to assess the changes in atrial tissue properties, arrhythmia vulnerability, and structure, along with miR-21 and its target genes, in HF caused by extensive myocardial infarction (MI) in rats, and (2) to determine whether miR-21 knockdown attenuates atrial fibrosis and AF promotion in this model.
Materials and Methods
For additional details, see the online-only Data Supplement.
Animals
Male Wistar rats, weighing 200 to 250 g (Charles River, SaintConstant, Quebec, Canada), were fed rat chow and housed under a 12:12-hour light/dark cycle at 21°C and 50% humidity. Rats had free access to tap water and food. Animal handling procedures followed the guidelines of the National Institutes of Health and were approved by the Montreal Heart Institute Animal Ethics Committee.
Surgical Procedures
Rats were anesthetized with 3% isoflurane, intubated, and ventilated after preoperative buprenorphine (0.03 mg/kg SC) injection. The thorax was shaved and sterilized with 2% w/v chlorhexidine gluconate in 70% v/v isopropyl alcohol. A left thoracotomy was performed, and the left anterior descending coronary artery was ligated with 6-0 silk. MI rats were compared with sham controls that underwent similar procedures but without left anterior descending ligation. The chest was closed with 3-0 silk and the skin closed with autoclips. Additional doses of buprenorphine (0.03 mg/kg) were administered subcutaneously 6 and 12 hours postoperatively.
Transthoracic Echocardiography
Transthoracic echocardiographic studies under 3% isoflurane were obtained before and 2 weeks and 8 weeks after surgery with a phasedarray 10S probe (4.5-11.5 MHz) in a Vivid 7 Dimension System (GE Healthcare Ultrasound, Horten, Norway).
Echocardiographic studies were used to select rats with large MIs. Left ventricular (LV) regional wall motion was scored in LV short axis for the 6 segments in this view as follows: (1) normal, (2) hypokinesia, (3) akinesia, (4) dyskinesia, and (5) aneurysmal. Wall motion score index (WMSI) was the mean value of all scores. Infarct size was classified as follows: small (1<WMSI≤1.25); medium (1.25<WMSI<1.65); or large (WMSI≥1.65). MI rats with WMSI <1.65 2 weeks after MI were excluded from the study.
Further analysis included LV dimensions (LV areas at end diastole and systole), systolic function (LV fractional area change), diastolic function (the mitral-valve inflow E-wave to early-diastolic mitralvalve annulus velocity ratio [E/Em ratio]), and myocardial performance index. Atrial analyses included left atrial (LA) dimension at end diastole and systole, right atrial dimension, and LA fractional shortening. Additional echocardiographic analyses and results are detailed in the online-only Data Supplement.
Hemodynamic Measurements
Systemic and intraventricular hemodynamic parameters were measured with 2.0F and 3.0F Millar catheters inserted into the right carotid artery, left ventricle (via right carotid artery), and right ventricle (via right jugular vein) in animals anesthetized with 2.5% to 3.0% isoflurane.
In Vivo Electrophysiology
Rats were intubated and ventilated under 3% isoflurane anesthesia. An octopolar catheter (1.9F) with 0.5-mm interelectrode spacing (Scisense) was inserted into the right atrium via jugular vein for stimulation and recording. A custom-built computer-based stimulator was used to trigger a stimulus isolator (Grass Telefactor model SD9K) with selected stimulation protocols. Atrial effective refractory period was determined (as the longest S1-S2 interval that failed to generate a response) with twice-threshold, 2-ms, square-wave pulses, 15-stimulus drive trains (S1) at 100-ms cycle length, followed by an S2 decremented in 2-ms intervals. We recorded surface ECG, intracardiac electrograms, and stimulus artifacts with IOX software (EMKA technologies, Paris, France) for monitoring and off-line analysis. In each animal, atrial effective refractory periods, Wenckebach cycle length, and corrected sinus node recovery time were determined with twice-threshold, 2-ms, square-wave pulses. AF was induced with up to 3 extrastimuli at a cycle length of 100 ms and, if that failed, atrial burst pacing. A standardized protocol was used (see the online-only Data Supplement for additional details). Rapid and irregular atrial rate (>500 beats per minute) with varying electrogram morphology characterized AF. The maximum AF duration in each animal was used to reflect the AF substrate. At the end of experiments, hearts were excised and immersed into buffered formalin or snap frozen in liquid N 2 for further analysis.
Histology
Hearts were preserved in 10% buffered formalin for paraffin embedment. Serial atrial tissue sections (12-μm thickness, 500-μm spacing) were stained with Masson Trichrome. Analysis of ×400 magnification images (15-20 from 3-5 sections) was performed with Image-Pro 6.2 software. Perivascular areas were avoided. Fibrous tissue content was expressed as a percentage of field area and averaged across fields for each rat.
Protein Extraction and Immunoblots
Protein extracts (100 μg) of snap-frozen LA tissue were separated by electrophoresis on 12% SDS-PAGE and transferred to nitrocellulose membranes (0.45 A). Membranes were blocked and incubated overnight with the primary antibodies and then with secondary antibodies. Antibody signals were visualized with enhanced chemiluminescence. Data were normalized to GAPDH band intensity from the same samples on the same membranes. The following primary antibodies were used: mouse anti-phospho-P38 mitogen-activated protein (MAP) kinase, mouse anti-phospho-ERK1/2 MAP kinase, mouse anti-P38 MAP kinase, mouse anti-ERK1/2 MAP kinase 
In Vivo MiR-21 Knockdown
Initial model characterization pointed to a role of miR-21 in adverse remodeling. Therefore, experiments were performed in 4 additional groups of rats: (1) sham-operated rats with a miR-21 knockdown probe anti-miR-21 (KD21; online-only Data Supplement Figure SI ) injected into LA myocardium; (2) sham-operated rats injected with scrambled control probe (Scr21); (3) MI rats injected with KD21; and (4) MI rats injected with Scr21. The KD21 probe was a locked nucleic acid 15-mer oligonucleotide (TCAGTCTGATAAGCT), with a complete phosphorothioate backbone purified by high-performance liquid chromatography. The Scr21 probe (CGTCTAGCCACCTAG), predicted bioinformatically not to interact with any other gene, was a negative control. Both constructs were custom synthesized with locked nucleotide chemistry by Exiqon (Vedbaek, Denmark). KD21 and Scr21 were dissolved in normal saline solution at 5 μg/μL. After thoracotomy, 10-μL solution was injected with a Hamilton microsyringe (31-gauge needle) into the LA wall at 5 separate injection points. In MI rats, left anterior descending ligation was performed after completing LA myocardial injections. In sham rats, LA myocardial injections were performed without left anterior descending ligation. After 2-or 8-week periods following MI, rats were submitted to echocardiography, in vivo electrophysiological study, and cardiac excision for histology or quantitative polymerase chain reaction.
Statistical Analysis
Variables fulfilling criteria for normal distribution (Shapiro-Wilks test) are expressed as mean±SEM; those that do not are expressed as median and first and third quartile (Q1-Q3) values delimiting bottom 25% and top 25% of the distribution. Analyses with nonrepeated measures data were performed with fixed-effects analysis of variance models. Linear mixed-effects models (MIXED procedure in SPSS 19.0; IBM, Armonk, NY) were used for analyses with repeated measures data. In both cases, main effect factors and all interactions were included. When a significant interaction or main effect was found, pairwise comparisons were performed with Bonferroni-corrected t tests (all P values shown are calculated P values×N, where N is the number of possible pairwise comparisons 
Results

Characterization of the Model
To characterize model evolution, serial echocardiograms were obtained at preoperative baseline, and 2 weeks and 8 weeks after MI. Key findings are shown in Figure 1A (Table 1) showed increased LV filling pressures and reduced pressure generation rates.
Representative Masson Trichrome images at 1, 2, 4, and 8 weeks after surgery in sham and MI rats are shown in Figure 1F . Fibrous tissue content increased significantly at 2 weeks after MI and remained elevated thereafter ( Figure 1G ).
Electrophysiology
Atrial effective refractory periods increased significantly after MI (P<0.001 for group effect; Table 2 ), with no time-related evolution during 2 to 8 weeks. Corrected sinus node recovery time was unaffected. Wenckebach cycle length also increased significantly after MI. Maximum AF duration per rat increased significantly 8 weeks after MI (online-only Data Supplement Figure SIII and Table 2 ).
Biochemistry
MAP kinase phosphorylation changes have been implicated in atrial fibrotic remodeling. 7, 8 To obtain mechanistic insights into atrial remodeling of HF rats after MI, we studied the changes in P38 and ERK1/2 expression and phosphorylation.
Original Western blots from 1-week after MI and corresponding sham rats are shown in Figure 2A , with corresponding temporal evolution data in Figure 2B to 2E. ERK1/2 phosphorylation increased 1 week after MI and returned to control values after 4 weeks. Total ERK1/2 expression also increased, but to a lesser extent than phospho-ERK1/2, 1 week after MI. P38 expression and phosphorylation were unchanged. Because miR-21 has been implicated in ventricular fibrosis after MI, acting via Sprouty-1 to cause ERK hyperphosphorylation, 16 we suspected the involvement of miR-21. Therefore, we measured the expression of miR-21, as well as that of its primary target Sprouty-1, in MI rats and corresponding shams at the time of steady-state fibrosis, 2 weeks after MI. MiR-21 expression was increased 2.5-fold in MI rats ( Figure 3A) , Sprouty-1 was strongly downregulated (Figure 3B ), and procollagen I and procollagen III were upregulated ( Figure 3C ), consistent with an important role of miR-21.
MiR-21 Knockdown
To assess more critically the participation of miR-21, we designed additional experiments to knock down LA miR-21 by injecting anti-miR-21 (KD21) into rat LA tissue at the time of coronary artery ligation, comparing the findings with KD21-injected contemporary sham rats, as well as sham and MI rats receiving Scr21 LA injections.
We first confirmed effective miR-21 knockdown ( Figure  4A ). LA miR-21 expression was increased at 2 weeks in Scr21 rats subjected to MI surgery in comparison with sham, indicating that injection of the scrambled sequence did not prevent miR-21 upregulation after MI. By 8 weeks after MI, there were no longer statistically significant miR-21 differences between MI and sham rats, consistent with the lack of fibrosis progression between weeks 2 and 8 ( Figure  1G ). KD21 suppressed miR-21 expression enhancement by MI, reducing the values in MI rats to those of sham rats injected with the scrambled probe. Corresponding changes in the AF-maintaining substrate are shown in Figure 4B and 4C. Figure 4B shows illustrative recordings of burst pacinginduced AF episodes from an Scr21 and a KD21 rat at 8 weeks after surgery. KD-21 significantly reduced maximal AF duration 8 weeks after MI to values comparable with those of sham rats ( Figure 4C ). Figure 5A shows representative Masson Trichrome images of LA samples from rats 8 weeks after surgery. Scr21-injected rats had substantial increases in LA fibrous tissue content versus matched shams. KD21 suppressed this fibrotic response, reducing fibrous tissue content by ≈66% versus Scr21-injected MI rats ( Figure  5B ). We also studied P-wave duration as an index of atrial conduction because atrial fibrosis promotes AF maintenance by affecting conduction. 7,9,18 KD21 significantly decreased P-wave duration ( Figure 5C ).
Intra-atrial KD21 administration did not significantly modify MI-induced increases in atrial effective refractory period and Wenckebach cycle length, nor did it affect corrected sinus node recovery time ( Figure 6 ). PR intervals, QRS durations, and QT intervals increased in MI rats, with no effect of KD21 administration, supporting atrial-predominant actions consistent with LA-directed KD21 administration (Figure 7) .
To further assess cardiac remodeling, we performed echocardiography in KD21 and Scr21-injected rats (online-only Data Supplement Figure SIV) . Similar to the basic characterization shown in Figure 1A and 1B, LA dimensions increased within 2 weeks in MI rats; these changes were unaffected by KD21. Similarly, LV function worsened after MI but was unaffected by KD21. These results indicate that the beneficial effects of miR-21 knockdown on the atrial arrhythmogenic substrate were not secondary to changes in ventricular function or the severity of HF, that LA dilation is not because of atrial fibrosis, and that AF substrate development can be prevented without attenuating LA enlargement.
Discussion
In this study, we characterized atrial profibrillatory remodeling in rats with MI-induced HF, observing changes compatible with profibrotic signaling via miR-21. We then tested the role of miR-21 directly, with atrial knockdown of miR-21. We found that miR-21 knockdown suppressed LA fibrotic remodeling, reducing tissue fibrosis and AF persistence significantly in rats with HF after MI.
Comparison With Previous Observations of Cardiac Remodeling in Related Models
MIs commonly induce LV dysfunction and HF in humans, causing a range of comorbidities, including AF. 19 Ventricular remodeling in rats roughly parallels corresponding phenomena in humans. 20 Milliez et al 21 reported LA enlargement associated with atrial fibrosis and ectopy that correlated with LV dysfunction in rats 3 months after MI. Boixel et al 22 noted that atrial fibrosis in rats after MI is associated with important hemodynamic disturbances and accumulation of matrix metalloproteinase-7. Atrial dilation and fibrosis are also prominent features in other experimental HF paradigms, such as ovine and canine ventricular tachycardiomyopathy. [23] [24] [25] [26] Both direct interference with cardiomyocyte bundle continuity and arrhythmogenic electrical interactions between cardiomyocytes and fibroblasts might contribute to AF promotion by atrial fibrosis.
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MicroRNAs and AF
MicroRNAs are important in a wide range of cardiac remodeling processes, 28 and there is increasing evidence for participation in AF. 13 I K1 upregulation contributes to AF stabilization because of electrical remodeling, 29 and miR-1 has been implicated, 30 although there is also evidence for a role of miR-26.
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I CaL downregulation is central to AF-related action potential abbreviation and AF promotion, 29 to which miR-328 upregulation may contribute. 31 It is also likely that miRs are important in atrial structural remodeling, particularly fibrosis. Several miRs may mediate cardiac fibrosis, with the most likely candidates being miR-21, miR-29, miR-133, miR-30, and miR-590. 32 MiR-133 and miR-590 may participate in atrial fibrotic remodeling caused by chronic nicotine exposure. 33 Here, we found that miR-21 is upregulated in the atrial profibrotic milieu caused by MI-associated HF and showed that suppression of miR-21 upregulation suppresses both atrial fibrosis and AF promotion. 
MiR-21 and Cardiac Remodeling
MiR-21 is involved in fibrotic remodeling of the lungs 34 and kidneys. 35 Thum et al 16 showed upregulation of miR-21 in a transverse aortic constriction model of HF. They also identified Sprouty-1 as a target of miR-21 and demonstrated Sprouty-1 repression by miR-21 in transfected cardiac fibroblasts. MiR-21 upregulation was associated with downregulation of Sprouty-1 and ERK hyperphosphorylation. Knockdown of cardiac miR-21 by tail-vein injection of miR-21 antagomir suppressed cardiac ERK phosphorylation, reduced interstitial fibrosis, and attenuated ventricular dysfunction. 16 The importance of miR-21 in ventricular remodeling was disputed by Patrick et al, 36 who showed that miR-21 knockout and inhibition by 8-nucleotide anti-miRs failed to prevent ventricular hypertrophic and fibrotic responses in mice subjected to pressure overload. In response, Thum et al 37 argued that miR-21 knockout from birth may be followed by adaptive responses, well recognized in knockout models, and showed that 8-nucleotide anti-miRs produce only modest and transient changes in miR-21 expression, resulting in lack of efficacy. Here, we used 15-nucleotide-locked nucleic acid-modified in vivo knockdown anti-miRs, which effectively prevented MIinduced upregulation of miR-21.
In the present study, we elected to use direct atrial myocardial injection of miR-21 anti-miR to avoid indirect atrial protection mediated by improved ventricular function as might occur after systemic anti-mir injection. Thum et al 16 noted improved LV function in transverse aortic constriction mice treated with systemic miR-21 antagomir injection. Indeed, ventricular dysfunction was unchanged in our KD21 rats compared with Scr21 controls (online-only Data Supplement Figure SIV) , excluding indirect effects secondary to improved hemodynamics and indicating direct participation of atrial miR-21 upregulation in AF-promoting atrial structural remodeling.
Novel Elements and Consideration of the Model
The present study is the first of which we are aware to directly demonstrate the role of an miR in AF-promoting atrial fibrotic remodeling. Furthermore, they constitute a proof of principle of the potential beneficial consequences of suppressing miR-21 upregulation in the prevention of AF. Interestingly, AF promotion was suppressed with reduced atrial fibrosis, despite persistent LA dilation. These findings are consistent with previous work in which AF promotion persisted along with continued atrial fibrosis, although LA dilation was reversed after hemodynamic recovery from HF. 38 These results suggest that atrial fibrosis is an essential factor in the HF-related AF substrate, providing support for upstream therapy that prevents or reverses atrial fibrosis in AF management. 39 Although systemic anti-miR-21 administration might protect against both HF-induced atrial structural remodeling and LV function impairment, 16 side effects of systemic administration might be a clinical problem. For example, antiapoptotic effects of miR-21 are needed for ischemic preconditioning 40 and prevent abdominal aortic aneurysm dilation. 41 Local administration, though technically challenging, could overcome these barriers and provide direct, tissue-specific miR-21 inhibition. We chose a rat HF model because reagent costs for miR-21 knockdown in larger animals like dogs or pigs would have been prohibitive. The ventricular tachycardiomyopathy model was unavailable because of a lack of implantable pacemakers appropriate for rats, so we employed a widely used MI model to induce HF. An advantage of the model of HF after MI is its potential relevance to HF in patients with prior MI, a common cause of clinical HF. 19, 20 To standardize infarct size and study animals with significant HF, we required large MIs based on echocardiographic WMSI for inclusion in the study. This decision had the advantage of creating a relatively uniform pool of animals: ventricular and atrial echocardiographic indices were well matched between KD21 and Scr21 rats (online-only Data Supplement Figure SIV) . The major disadvantage was a high drop-out rate: only ≈1/3 of rats had sufficiently large MIs. Combined with a high early mortality rate in rats with large MI (≈50% within 24 hours), this approach greatly limited the numbers of animals we could study.
Because of species-and disease-specific considerations, our results should not be extrapolated directly to other models of atrial fibrosis/AF. Further investigation will be needed to assess their applicability to clinical AF and other experimental HF paradigms. Although our data strongly support a significant role of miR-21 in atrial fibrotic remodeling in MI-related HF, they do not exclude contributions from other miRs, which remain to be addressed in future work.
Our results show that the inhibition of atrial fibrosis by suppression of miR-21 upregulation coincides with prevention of AF substrate formation in this rat model of HF due to MI. These findings do not prove that fibrosis mitigation mediated the anti-AF effects. For example, benefit may have been because of the prevention of fibroblast proliferation and fibroblast-cardiomyocyte electrical interaction. 22 Similarly, additional atrial protective effects or remote nonatrial actions cannot be completely excluded based on our results. That fibrosis alone is insufficient to sustain AF in our model is indicated by the fact that fibrosis reached a maximum 2 weeks after MI ( Figure 1G ) but AF duration did not increase significantly until 8 weeks after MI ( Figure 4C and online-only Data Supplement Figure SIII) . The echocardiographic data showing progressive LA dilation between weeks 2 and 8 point to LA enlargement as a factor that may also have been required for AF substrate development. The simplest explanation of our results is that both fibrosis and LA enlargement are needed for the AF substrate; thus, at 2 weeks (when there is fibrosis but insufficient LA enlargement) or 8 weeks after MI+KD21 administration (when insufficient fibrosis has developed despite substantial LA enlargement) prolonged AF does not occur.
Conclusions
Atrial fibrosis and AF promotion in rats with HF after MI are associated with miR-21 and target gene expression changes consistent with miR-21 signaling. Suppression of MI-induced miR-21 upregulation prevents atrial fibrosis and AF promotion. These findings implicate miR-21 as a significant signaling molecule in atrial profibrillatory remodeling and establish it as a potentially interesting target for AF-preventing therapy.
